- Home
- EXEL vs IVZ Comparison
EXEL vs IVZ Comparison
Compare EXEL & IVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- IVZ
- Stock Information
- Founded
- EXEL 1994
- IVZ 1935
- Country
- EXEL United States
- IVZ United States
- Employees
- EXEL N/A
- IVZ N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- IVZ Investment Managers
- Sector
- EXEL Health Care
- IVZ Finance
- Exchange
- EXEL Nasdaq
- IVZ Nasdaq
- Market Cap
- EXEL 10.4B
- IVZ 9.9B
- IPO Year
- EXEL 2000
- IVZ 1995
- Fundamental
- Price
- EXEL $37.88
- IVZ $22.83
- Analyst Decision
- EXEL Buy
- IVZ Hold
- Analyst Count
- EXEL 22
- IVZ 16
- Target Price
- EXEL $44.00
- IVZ $21.55
- AVG Volume (30 Days)
- EXEL 2.4M
- IVZ 4.1M
- Earning Date
- EXEL 10-28-2025
- IVZ 10-28-2025
- Dividend Yield
- EXEL N/A
- IVZ 3.52%
- EPS Growth
- EXEL 81.76
- IVZ N/A
- EPS
- EXEL 2.08
- IVZ 0.93
- Revenue
- EXEL $2,230,005,000.00
- IVZ $6,153,100,000.00
- Revenue This Year
- EXEL $9.10
- IVZ N/A
- Revenue Next Year
- EXEL $12.47
- IVZ $10.98
- P/E Ratio
- EXEL $18.54
- IVZ $25.71
- Revenue Growth
- EXEL 10.73
- IVZ 5.83
- 52 Week Low
- EXEL $25.17
- IVZ $11.60
- 52 Week High
- EXEL $49.62
- IVZ $24.54
- Technical
- Relative Strength Index (RSI)
- EXEL 38.92
- IVZ 50.70
- Support Level
- EXEL $38.35
- IVZ $23.76
- Resistance Level
- EXEL $41.44
- IVZ $24.54
- Average True Range (ATR)
- EXEL 0.97
- IVZ 0.61
- MACD
- EXEL -0.26
- IVZ -0.04
- Stochastic Oscillator
- EXEL 2.48
- IVZ 34.09
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (68% of managed assets) and institutional (32%) clients. At the end of July 2025, the firm had $2.025 trillion in assets under management spread among its equity (60% of AUM), balanced (3%), fixed-income (21%), alternative investment (6%), and money market (10%) operations. Passive products account for 46% of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).